New prognostic factors and developing therapy of cutaneous melanoma

The multiple molecular alterations underlying the neoplastic process and clinical characteristics of cutaneous melanoma are currently under intensive investigation. Recent studies have demonstrated that the levels of melanoma-associated proteins in tumor tissue or in patient serum can serve as new markers to predict disease outcome. Similarly, the expression of thousands of genes in melanoma tumors can be surveyed simultaneously using DNA arrays, allowing molecular profiling of individual tumors, which gives the possibility of classifying melanomas based on their biological diversity. Large clinical studies have also identified multiple prognostic factors, such as tumor ulceration, and led to development of a new, more precise melanoma staging system, which emphasizes the biological characteristics of the primary disease. These new findings may have an important role in earlier measurement of the clinical response and provide a basis for tailored melanoma therapy, the development of which will also be discussed in this review.     

YWHAZ在皮肤黑色素瘤中的临床及生物学意义

目的探讨YWHAZ在皮肤黑色素瘤中的表达及其临床意义,初步检测YWHAZ在皮肤黑色素瘤中的生物学功能。 方法使用GEO数据库分析YWHAZ在皮肤黑色素瘤与良性痣间的表达差异,使用TCGA皮肤黑色素瘤数据集分析YWHAZ表达与皮肤黑色素瘤患者总生存之间的相关性。通过体外实验,敲减YWHAZ在皮肤黑色素瘤细胞中的表达,CCK8法检测细胞增殖,流式检测细胞凋亡,Transwell实验检测细胞迁移及侵袭能力改变。 结果黑色素瘤组织中YWHAZ的平均相对表达量5.785±0.128,明显高于良性痣中YWHAZ的平均相对表达量（4.704±0.281）,差异有统计学意义（t=4.023,P=0.0002）;YWHAZ高表达组中位生存期（47.28个月）较低表达组（89.13个月）明显缩短（P=0.0085）。体外实验结果显示YWHAZ敲减后黑色素瘤细胞增殖减慢、凋亡细胞比例增加、迁移及侵袭能力减弱。 结论YWHAZ在皮肤黑色素瘤中发挥癌基因的作用,降低YWHAZ表达水平可抑制黑色素瘤的恶性表型。     

(m)HAD方案诱导治疗急性单核细胞白血病的疗效及与染色体核型分组关系分析

目的 分析(m)HAD方案诱导治疗急性单核细胞白血病(AMOL)的疗效及染色体核型对预后的影响.方法 对79例用(m)HAD方案诱导治疗的AMOL患者临床资料进行回顾性分析.(m)HAD方案具体为高三尖杉酯碱2 mg/m2,第1～7天;阿糖胞苷100 mg/m2,第1～7天,部分患者于第5、6、7天改为1.5 g·m-2·(12 h)-1;柔红霉素40 mg/m2,第1～3天.结果 ①诱导化疗完全缓解(CR)率79.7%(79例中63例),部分缓解(PR)率6.3%(79例中5例),总有效率86.0%.②对75例患者进行染色体核型分析,正常核型43例,异常核型30例,未见分裂象2例;预后中等组49例,预后差组18例,意义未知组6例.核型正常者CR率及1年、3年总体生存(OS)率明显高于核型异常者(P<0.05);但两组在无病生存(DFS)方面差异无统计学意义(P>0.05).染色体核型预后中等组患者CR率85.7%,1年、3年OS率分别为75.9%、65.4%,DFS率分别为82.2%、77.9%,均明显好于预后差组(CR率61.1%,1年、3年0s率分别为51.3%、25.6%;1年、3年DFS率分别为66.7%、26.7%)(P<0.05).③COX多因素分析显示,染色体核型、巩固治疗疗程数对生存有显著的影响.结论 采用(m)HAD方案诱导治疗AMOL患者,CR率高,缓解后巩固治疗是否充分明显影响患者的预后.AMOL患者异常核型发生率和既往报道的急性髓系白血病群体发生率相似,且染色体核型同样与预后密切相关,预后中等组明显优于预后差组.

Abstract：

Objective To analyze the treatment outcome and impact of cytogenetic abnormalities on the response and survival of acute monocytic leukaemia (AMOL) patients received (m)HAD regimen as induction chemotherapy. Methods Seventy-nine AMOL patients were treated with (m) HAD regimen as induction therapy ( HHT 2 mg/m2, d 1-7; Ara-C 100 mg/m2,d 1-7 and increasing to 1. 5 g · m-2 ·(12h)-1,d5-7 in some patients; DNR 40 mg/m2, d 1 - 3). The treatment outcome and prognostic factors were analyzed. Results ①The complete remission( CR) rate was 79.7% (63/79), partial remission (PR)rate was 6.3% (5/79) ,overall rate was 86.0%. ②The chromosome karyotypes were analyzed in 75 patients,of whom 43 with normal karyotypes (NCR) and 30 abnormal karyotypes ( ACR). For the cytogenetic prognostic groups, 49 patients were intermediate, 18 poor and 6 unknown. The CR,1-year and 3-year overal survival (OS)rates in NCR group were significantly higher than those in ACR group(P <0.05);but there was no significantly statistical difference in disease free survival ( DFS) between the two groups (P > 0. 05). The CR,1-year OS 、3-year OS and 1-year DFS and 3-year DFS rates in intermediate prognostic group were significantly higher than those in poor prognostic group (85. 7% vs 61. 1% , 75. 9% vs 51. 3% , 65. 4% vs 25. 6% ,82.2% vs 66.7% , and 77. 9% vs 26. 7% , respectively) ( P < 0. 05). ③Chromosome karyotype and the number of consolidation therapy courses had more important influence on survival in COX analysis. Conclusion (m)HAD regimen as induction chemotherapy for AMOL patients achieves a high CR rate. It has an important influence on survival for the patients to reveive adequate consolidation therapy. The frequency of cytogenetic abnormalities in AMOL is similar to that in other AMLs. The prognosis of AMOL patients with chromosome karyotype in intermediate prognostic group is significantly better than that in poor prognostic group.     

The clinical recognition and prognostic factors of primary cutaneous malignant melanoma

The incidence of melanoma continues to increase. In the absence of a defined and preventable etiology, early recognition and proper management offer the best hope for prolonged survival and cure. Clinically suspect lesions must be biopsied for diagnostic confirmation and histologic information. Reliable prognostic information can be gained from histologic and clinical parameters, which are described.     

Early and late relapses of cutaneous melanoma patients

Objectives: Recurrence may most likely develop during the course of the disease in patients presented with early stage melanoma at initial diagnosis. The specific risk factors for early and late recurrences following definitive surgical excision have yet to be determined. The aim of this study was to analyze the early and late relapses in stage I-III cutaneous melanoma patients.

Methods: Of 365 patients with relapses, 189 developed within the first 18 months following surgical intervention (early relapse [ER]) and the remaining 176 occurred later (late relapse [LR]) were analyzed.

Results: ER patients were found to have thicker and ulcerated lesions with higher mitotic rates and lymphovascular invasion, and they were found to be more significantly associated with node involvements. Nearly half of the first recurrences were locoregional (49.9%) that were followed by distant metastases alone (26.6%). The distribution of the initial relapse patterns was similar between the ER and the LR groups. The lung was the most frequently metastasized site (43.1%), and it was followed by bone (21.0%), liver (20.7%) and brain (15.1%). On multivariate analysis risk factors in association with both ER and LR were found as follows: ulcerated lesions, high mitotic rate, and node-positive disease; however nodular histopathological subtype and lymphovascular invasion were found to have impact merely on ER, and male gender merely on LR.

Conclusion: The current study has detected potential risk factors for relapse of patients who developed ER and LR. These indicators may be useful for rational follow-up programs of the patients.     

肛管直肠恶性黑色素瘤9例报道

目的 :探讨肛管直肠恶性黑色素瘤的治疗方法。方法 :回顾分析我院收治的 9例恶性黑色素瘤病人的治疗及预后情况。结果 :本组病人预后差 ,生存期短 ,手术加免疫治疗效果优于单纯手术或手术加放化疗。结论 :恶性黑色素瘤病人治疗以手术为主 ,Miles术后和经肛门局部切除术是常选用的两种术式 ,手术同时辅助采用免疫治疗效果更好     

亚低温治疗在脑复苏中的应用及影响预后因素分析

目的 探讨影响心肺复苏(CPR)术后亚低温治疗患者预后的因素及动态脑电波监测对预后的价值.方法 对42例循环稳定的CPR术后患者在全身治疗的基础上进行亚低温治疗,体温(颈静脉球温度)控制在31～34℃,维持3～6 d后复温.治疗期间行各项常规检查,同时监测脑电波并进行Hockday分级,对于存活3个月者通过格拉斯哥预后评分(GOS)评估神经系统功能.结果 良好转归组(包括恢复良好、中度残疾,19例)与不良转归组(包括严重残疾、植物状态、死亡,23例)间停跳后至开始CPR时间及复苏后格拉斯哥昏迷评分(GCS)、血中剩余碱、乳酸浓度均存在不同程度差异[停跳后至开始CPR时间(min):4.11±1.80比13.08±11.37,GCS(分):5.48±1.32比4.13±1.61,剩余碱(mmol/L):-10.27±6.23比-13.18±7.29,乳酸(mmol/L):6.82±3.12比8.47±4.14,P＜0.05或P＜0.01];37例患者行动态脑电波监测,Hockday分级Ⅱ级与Ⅲ级间的良好预后率比较差异有统计学意义[85.7%(12/14)比37.5%(3/8),P＜0.05].结论 停跳后至开始CPR时间及复苏后GCS、血中剩余碱、乳酸浓度有助于判定亚低温治疗后患者的预后;脑电波监测对判定亚低温治疗后患者神经功能转归有较大帮助.     

视网膜母细胞瘤的生存率和预后因素研究

目的研究视网膜母细胞瘤(Rb)的生存率及预后因素。方法随访1997～2001年102例Rb患者的生存状况,进行Rb的生存率和相关预后因素分析。结果随访102例Rb患者,平均随访时间为45.2个月。81例存活(79.4%),21例死亡(20.6%);1、3、5年的生存率分别为87.25%、81.37%和78.79%。单眼、双眼患者生存率分别为84.52%和54.55%,差异有统计学意义(P<0.01);病程≤6个月的生存率为85.36%,病程>6个月的生存率为58.33%,两者差异有统计学意义(P<0.01);12例眶组织侵犯,存活5例,死亡7例,生存率为41.67%,眶组织未受侵犯组生存率为83.78%,两者差异有统计学意义(P<0.01);10例进行眼球保守治疗,5例成功;93例Ⅰ期行眼球摘除术的患者中,84例行Ⅰ期义眼座植入术,其中73例(86.9%)存活,11例(13.1%)死亡。结论 102例Rb患者42个月后生存率达到78.72%。双眼患者、病程>6个月和眶组织侵犯者预后较差,生存率低。Rb患者有一定的保守治疗成功率,Rb患者行眼球摘除术时,可选择联合行Ⅰ期义眼座植入。     

动脉粥样硬化基因治疗与影像学

从基因水平探索动脉粥样硬化性疾病的有效治疗方法是当今医学研究的热点及方向。从基因治疗的靶点、载体、传送技术及影像学在其中的作用等方面介绍了目前血管基因治疗影像学的研究近况。     

脓毒症并发急性肾损伤患者临床特点及预后因素分析

目的 探讨脓毒症并发急性肾损伤（AKI）患者的临床特点及其影响预后的因素. 方法 回顾性分析2006年12月至2011年10月入住温州医科大学附属第一医院急诊重症监护室的脓毒症并发AKI患者90例.用单因素及多因素Logistic回归分析研究其临床特点及影响预后的危险因素. 结果 90例脓毒症并发AKI患者的感染诱因主要为腹内感染、肺部感染、皮肤及软组织感染;AKI 2、3期病死率明显高于1期（P＜ 0.05）;32例患者接受了肾脏替代治疗,44例患者需机械通气支持,45例死亡（病死率为50.0％）.单因素分析提示器官衰竭数目、AKI分期、应用血管活性药物、是否需要机械通气支持都能影响患者预后（P均＜0.05）.多因素Logistic回归分析显示,器官衰竭数目（P=0.008,OR=2.181）、AKI分期（P=0.011,OR=2.227）、是否需要机械通气支持（P=0.002,OR=0.198）是患者死亡的独立危险因素. 结论 器官衰竭数目、AKI分期及需机械通气支持可作为判断脓毒症并发AKI患者预后的重要依据.     

Course and prognostic factors of whiplash: a systematic review and meta-analysis

We conducted a systematic review and meta-analysis of prospective cohort studies of subjects with acute whiplash injuries. The aim was to describe the course of recovery, pain and disability symptoms and also to assess the influence of different prognostic factors on outcome. Studies were selected for inclusion if they enrolled subjects with neck pain within six weeks of a car accident and measured pain and/or disability outcomes. Studies were located via a sensitive search of electronic databases; Medline, Embase, CINAHL, Cochrane database, ACP Journal club, DARE and Psychinfo and through hand-searches of relevant previous reviews. Methodological quality of all studies was assessed using a six item checklist. Sixty-seven articles, describing 38 separate cohorts were included. Recovery rates were extremely variable across studies but homogeneity was improved when only data from studies of more robust methodological quality were considered. These data suggest that recovery occurs for a substantial proportion of subjects in the initial 3 months after the accident but after this time recovery rates level off. Pain and disability symptoms also reduce rapidly in the initial months after the accident but show little improvement after 3 months have elapsed. Data regarding the prognostic factors associated with poor recovery were difficult to interpret due to heterogeneity of the techniques used to assess such associations and the way in which they are reported. There was also wide variation in the measurement of outcome and the use of validated measures would improve interpretability and comparability of future studies.     

持续腹膜透析患者的生存率及多变量预后分析

目的分析腹膜透析患者的生存率及其独立的预后因素,观察腹膜转运特性及相关临床特点对患者生存的影响。方法选择北京协和医院肾内科随诊腹膜透析患者232例,采用Cox模型回归分析透析开始时各临床指标对生存时间的影响。结果CAPD患者1年、2年、3年及4年总体生存率分别为91.1%、77.7%、68.7%及55.8%;单因素COX模型回归分析表明：糖尿病患者、腹膜高转运状态、年龄增加、血浆白蛋白低于3.0的患者预期生存率均降低（P〈0.05）。232例患者中180（78%）位患者在开始透析的前6个月完成腹膜平衡实验（PET）,其中高转运状态与死亡显著相关（与低于平均转运患者相比,RR2.70;95% CI 1.03 to 7.05;P=0.043）。经多因素COX模型回归分析,糖尿病和年龄是尿毒症腹膜透析患者死亡的独立危险因素。糖尿病患者死亡的相对危险度为非糖尿病患者的2.96倍（95% CI 1.62 to 5.38;P〈0.0001）;年龄每增加10岁,相对危险度增加0.31（P=0.039）。结论根据透析前年龄、原发病、血清白蛋白和腹膜的转运状态可以对腹膜透析患者的预后进行初步判断。     

成人急性淋巴细胞白血病的化疗及预后因素分析

目的 分析成人急性淋巴细胞白血病(ALL)的临床特点,比较不同化疗方案组患者的疗效,探讨影响长期生存的因素.方法 回顾性分析1998年6月至2005年12月住院治疗的成人ALL患者149例.采用SPSS11.5统计软件分析有关数据.结果 ①133例患者进行了免疫表型分析,其中B细胞表型118例(88.7%),T细胞表型15例(11.3%).有染色体核型结果的患者105例,正常核型40例(38.1%),异常核型65例(61.9%).②按诱导治疗方案不同将治疗满4周的患者分为VDCP、VDLP、VDCLP三组,诱导治疗总完全缓解(CR)率为93.7%.三组患者诱导治疗1个疗程结束时CR率分别为80.8%、92.3%、81.4%,差异无统计学意义(P=0.618).包含和不包含门冬酰胺酶的诱导方案诱导治疗结束时CR率分别为95.5%和92.1%,差异无统计学意义(P=0.566).患者中位无病生存(DFS)期为12(1～74)个月,中位总生存(OS)期为17.5(1～97)个月.三组患者3年及5年DFS率分别为18.5%和14.8%、24.7%和9.9%、39.5%和39.5%,组间差异有统计学意义(P=0.0066).③通过COX回归模型分析显示患者就诊时年龄＞40岁、WBC＞40×109/L、染色体t(9;22)及巩固治疗不足4个疗程为预后不良因素.结论 成人ALL免疫表型检测以B-ALL为主,染色体核型变化较大.多数患者在接受4或5种药物联合的诱导方案治疗后可获CR;用门冬酰胺酶不影响诱导治疗CR率,但可提高患者的DFS和OS率.染色体核型异常影响患者生存情况.充分的巩固强化治疗对延长生存期必不可少.就诊时的年龄、白细胞计数、染色体核型检查结果及巩固治疗疗程数为影响生存的预后因素.     

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer

BACKGROUNDBreast cancer mainly occurs in young and premenopausal women; its incidence is increasing annually. Patients with triple-negative breast cancer (TNBC) have relatively high recurrence and transfer rates during the operation and 3 years after postoperative adjuvant chemotherapy. Currently, the treatment for patients with TNBC is mainly based on a comprehensive combination of surgery and chemotherapy. Therefore, identifying additional effective treatments to improve patient prognosis is important. AIMTo explore and discuss the effects and prognostic factors of neoadjuvant chemotherapy in TNBC.METHODSIn total, 118 patients diagnosed with TNBC from January 2016 to January 2020 in our hospital were selected and divided into the observation (n = 60) and control (n = 58) groups according to therapeutic regimen. The control group received routine chemotherapy, and the observation group received neoadjuvant chemotherapy. The therapeutic effects of the two groups were observed, and the survival of patients was followed up.RESULTSThe karyopherin A2 (KPNA2)-positive and SRY-related HMG box-2 (SOX2)-positive expression rates of patients with TNBC with intravascular tumor thrombus and tumor-node-metastasis (TNM) stage IV were 92.00% and 91.67% and 96.00% and 95.83%, respectively, which were significantly higher than those of patients with no intravascular tumor thrombus and TNM stage III (P < 0.05). KPNA2 was positively associated with SOX2 expression (r_s = 0.514, P < 0.50). The short-term curative effect of the observation group was better than that of the control group (P < 0.05), and the total effective rate was 58.33%. After treatment, carcinoembryonic antigen, cancer antigen (CA) 19-9, and CA125 Levels in the observation group were 11.40 ± 2.32 mg/L, 19.92 ± 3.42 kU/L, and 54.30 ± 12.28 kU/L, respectively, which were significantly lower than those in the control group (P < 0.05). The median survival time of the observation group was 33 mo (95%CI: 31.21-34.79), which was significantly longer than that of the control group (P < 0.05). TNM stage, degree of differentiation, lymph node metastasis, KPNA2 and SOX2 expressions, and treatment plan were prognostic factors of TNBC (relative risk = 1.575, 1.380, 1.366, 1.433, 1.411, and 0.581, respectively, P < 0.05).CONCLUSIONNeoadjuvant chemotherapy for TNBC treatment can achieve good curative effects. TNM stage, differentiation degree, lymph node metastasis, KPNA2 and SOX2 expressions, and treatment plan are prognostic factors of TNBC.     

Ultrasound and cisplatin combined treatment of human melanoma cells A375--the study of sonodynamic therapy

Sonodynamic therapy, an effect of low-power ultrasound field and the anticancer drug cisplatin, was studied in vitro on human melanoma cells A375. The viability of cells has been studied by standard 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide viability assay according to different modes of treatment: application of cisplatin alone, exposure of ultrasound field alone, exposure to ultrasound followed by cisplatin and application of cisplatin followed by exposure to ultrasound. Ultrasound was used at a therapeutic intensity of 1 W?cm⁻² for 10 min. Concentration of cisplatin in the cell suspension was always 2.3 μM. The results show that sonodynamic therapy is one of the possibilities of how to intensify standard cytostatic therapy. This conclusion is supported by reducing the viability of studied cells, especially 72 h after the treatment. The time sequence of application of ultrasonic field and cytostatics appears to be a significant factor affecting the changes in cell viability. Maximum suppression of viability has been found when applying the experimental design involving application of cisplatin followed by exposure to ultrasound; the final value of viability of combined affected cells was more than 10% lower than for cisplatin treatment alone.     

鼻咽癌远期生存率及预后因素分析

目的:通过分析我院鼻咽癌患者情况,了解本院鼻咽癌疗效及预后影响因素.方法:收集1996年4月1日至2007年3月1日期间住院治疗的238例初治鼻咽癌患者资料,Kaplan-Meier法进行生存分析.Log-Rank法检验生存率之间的差异.Cox回归模型进行多因素分析.结果:1、3、5、8、10年的总生存率分别为95.6％、85.2％、76.6％、63.2％和58.3％.单因素分析显示年龄、T分期、N分期和总分期是影响鼻咽癌患者预后的危险因素.Cox多因素分析显示年龄、T分期、N分期是独立预后危险因素.结论:我院鼻咽癌治疗水平与文献报告相当.重视治疗过程中的年龄因素和分期因素,早诊早治可能有助于提高鼻咽癌疗效.     

新型布尼亚病毒感染患者25例临床特征及预后因素分析

目的探讨新型布尼亚病毒感染的临床特点及其预后相关影响因素。 方法选取金华地区2011年8月至2017年12月确诊的新型布尼亚病毒感染患者25例,根据患者的生存情况,将25例患者分为痊愈组（15例）与死亡组（10例）。比较痊愈组和死亡组患者的一般资料,症状体征,实验室检查包括白细胞计数、中性粒细胞、血红蛋白、血小板计数、总胆红素、直接胆红素、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、AST/ALT、肌钙蛋白I、乳酸脱氢酶、肌酸激酶、肌酸激酶同工酶（CK-MB）、凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、D-二聚体、肌酐及尿蛋白,治疗及预后情况,采用受试者工作特征（ROC）曲线分析预后的相关影响因素。 结果痊愈组出现意识障碍患者显著低于死亡组（1/15 vs. 7/10,P=0.002）,AST/ALT [1.80（1.38,3.16）vs. 3.27（1.97,4.84）,H=1.997,P=0.046]、肌钙蛋白I [0.04（0.02,0.25）ng/L vs. 0.63（0.49,1.19）ng/L,H=3.328,P=0.001]、肌酸激酶[836.00（318.00,1 462.00）U/L vs. 2 486.00（590.25,3 417.00）U/L,H=2.302,P=0.021]、CK-MB [33.00（25.00,52.00）U/L vs. 66.50（38.25,104.50）U/L,H=1.970,P=0.049]、PT [11.70（10.90,12.20）s vs. 14.35（12.53,15.63）s,H=2.719,P=0.007]及APTT [44.70（34.20,53.20）s vs. 79.00（60.05,105.55）s,H=3.439,P=0.001]表达水平亦均显著低于死亡组。将AST/ALT、肌钙蛋白I、肌酸激酶、CK-MB、PT及APTT纳入ROC曲线分析,结果显示,AST/ALT [曲线下面积（AUC）= 0.740,95%置信区间（CI）（0.525,0.955）,P=0.046]、肌钙蛋白I [AUC=0.900,95%CI（0.777,0.987）,P=0.001]、肌酸激酶[AUC=0.777,95%CI（0.570,0.983）,P=0.021]、CK-MB [AUC=0.737,95%CI（0.519,0.954）,P=0.049]、PT [AUC=0.817,95%CI（0.654,0.923）,P=0.007]及APTT [AUC=0.913,95%CI（0.804,0.993）,P=0.001]均对新型布尼亚病毒感染患者预后具有预测价值。其中,肌钙蛋白I和APTT的AUC分别为0.900和0.913,对预后的预测能力均较好。 结论金华地区人感染新型布尼亚病毒患者多病情重、死亡比例高、临床症状多样,其中AST/ALT、肌钙蛋白I、肌酸激酶、CK-MB、PT及APTT是预后的重要影响因素。     

乳腺癌超声毛刺征部位胶原纤维增生与预后因素的关系

目的 探讨乳腺癌超声毛刺征部位胶原纤维增生程度与预后因素间的关系。方法 收集经病理证实的60例乳腺癌,术前超声检查证实肿块周边毛刺征,并在超声引导下于毛刺处穿刺活检,根据胶原纤维组织增生程度将其分为胶原纤维轻度、中度和重度增生。分析乳腺癌超声毛刺征处胶原纤维组织增生程度与预后因素（癌灶大小、组织学分级、淋巴结转移和免疫组化分子标志物表达）之间的关系。结果 乳腺癌毛刺处胶原纤维组织轻度、中度与重度增生患者间,组织学分级、癌灶大小、淋巴结转移差异均有统计学意义（P均<0.05）;重度增生患者肿瘤组织学分级较高、肿瘤较大、淋巴结转移者较多。乳腺癌毛刺处纤维组织轻度、中度与重度增生患者之间,雌激素受体（ER）及人表皮生长因子受体-2（HER-2/neu）表达差异有统计学意义（P均<0.05）,重度增生患者ER表达低,HER-2/neu表达高;而孕激素受体（PR）、Ki-67表达差异均无统计学意义（P均>0.05）。结论 乳腺癌毛刺处胶原纤维增生程度与预后密切相关,胶原纤维增生严重提示乳腺癌预后较差。